Sandoz, the Swiss giant in the field of generic and biosimilar medicines, has made a significant move in the US market with the launch of Wyost and Jubbonti – the first interchangeable denosumab biosimilars approved by the Food and Drug Administration (FDA). These biosimilars have been approved to treat all indications of Amgen’s blockbuster medicines, […]
